Prospective, Double-Blind, Randomized, Parallel-Group, DoseRanging Study of Botulinum Toxin Type A in Men with
Glabellar Rhytids
ALASTAIR CARRUTHERS, MD,✽ AND JEAN CARRUTHERS, MD†
Departments of ✽Dermatology and †Ophthalmology, University of British Columbia, Vancouver, British Columbia,
Canada
BACKGROUND.
The effective dose for treating glabellar lines with
botulinum toxin type A in men has not been studied adequately.
OBJECTIVE . To compare the safety, efficacy, and duration of
response of four doses of botulinum toxin type A on glabellar
rhytids in men.
METHODS. Eighty men were randomized to receive a total dose of
either 20, 40, 60, or 80 U of botulinum toxin type A (BOTOX,
BOTOX Cosmetic, or Vistabel, Allergan, Inc., Irvine, CA, USA)
in the glabellar area. Glabellar lines were assessed at rest and
maximum frown by a trained observer at baseline, 2 and 4
weeks, and monthly thereafter. Patients provided self-evaluations
at the same visits. Adverse events were monitored throughout.
RESULTS. The 40, 60, and 80 U doses of botulinum toxin type A
were consistently more effective in reducing glabellar lines than
the 20 U dose (duration, peak response rate, improvement from
baseline). There was a dose-dependent increase in both the
response rate at maximum frown and the duration of effect
assessed by the trained observer. In addition, the participants
reported a dose-dependent reduction in the ability to frown,
improvement in their global assessment, and increased feelings of
attractiveness, self-confidence, and satisfaction. The incidence of
adverse events was not increased with higher doses.
CONCLUSION. Male participants with glabellar rhytids benefit
from starting doses of at least 40 U of botulinum toxin type A.
ALASTAIR CARRUTHERS, MD, AND JEAN CARRUTHERS, MD, ARE CONSULTANTS FOR ALLERGAN, INC.
THE EFFICACY and safety of botulinum toxin type A for
the esthetic treatment of hyperfunctional facial lines,
including glabellar lines, have been demonstrated in
numerous trials. In two multicenter, double-blind, randomized, placebo-controlled trials in which more than 500
participants were treated, 20 U of botulinum toxin type A
was found to be a highly effective dose in a mostly female
study population.1–3 Dose titration and its effect on treatment intervals have not, however, been standardized, nor
have recommendations for dose adjustments on the basis
of gender been developed.
The efficacy and safety of varying doses of botulinum
toxin type A in the treatment of glabellar lines in women
were recently characterized in a double-blind, randomized,
dose-ranging study.4 In that study, a 10 U total dose was
less efficacious than total doses of 20, 30, and 40 U. The
peak response to treatment and the duration of the benefit were dose dependent, but there were no dose-related
differences in adverse effects, supporting the use of at least
20 U total dose of botulinum toxin type A in female participants.
Address correspondence and reprint requests to: Alastair Carruthers,
MD, University of British Columbia, 943 West Broadway, Suite 820,
Vancouver, BC V5Z 4E1, or e-mail: alastair@carruthers.net.
Clinical experience suggests that men require a higher
total dose. Because no more than approximately 20% of
participants in clinical trials have been male, the optimal
dosing in men remains to be determined. Therefore, we
conducted this trial of botulinum toxin type A to compare
the safety and efficacy of four doses of botulinum toxin
type A in men and to evaluate whether the duration of
response was dose dependent. The lowest total dose of 20
U was selected based on the results of the dose-ranging
study in women and on our clinical observations in men.
Methods
Study Design
A single-center, prospective, double-blind, randomized,
parallel-group, dose-ranging study of up to 52 weeks’
duration.
Patients
Men between 18 and 65 years of age were eligible for the
study. Glabellar rhytids were judged by a trained observer
as moderate or severe on the Facial Wrinkle Scale (FWS)
during maximum attempted muscle contraction.
Key exclusion criteria included the use of any agent (eg,
aminoglycoside antibiotics) that could interfere with neu-
© 2005 by the American Society for Dermatologic Surgery, Inc. • Published by BC Decker Inc
ISSN: 1076–0512 • Dermatol Surg 2005;31:1297–1303.
1298
CARRUTHERS, J. AND A.: DOSE-RANGING STUDY OF MALE GLABELLAR RHYTIDS
romuscular transmission or any condition (eg, EatonLambert syndrome, myasthenia gravis, excessive weakness, or atrophy of target muscles) that could amplify the
effects of treatment with botulinum toxin type A. Individuals were also excluded if they had any known allergy or
sensitivity to any component of the study medication; had
prior cosmetic procedures, soft tissue augmentation, or
visible scars on the treatment area; or had received treatment with botulinum toxin within 1 year of baseline evaluation.
Any subject could be withdrawn from the study at any
time in the event of a serious adverse event. They could also
be withdrawn if any exclusion criteria became apparent or
on voluntary discontinuation. Subjects who were withdrawn before the initiation of treatment could be replaced.
The study complied with the Declaration of Helsinki
recommendations for biomedical research involving
human subjects. Institutional Review Board approval was
obtained at the site before the start of the study. The design
of the study, objectives, and potential risks were explained
to potential subjects, and written informed consent was
obtained prior to enrolment.
Dermatol Surg
31:10:October 2005
stitution. Nonpreserved saline was used because this is the
method of reconstitution recommended in the package
insert,1 and this was the diluent we used in the similar
female study.4
Follow-Up and Outcome Measures
The study comprised a screening/baseline visit and postinjection follow-up visits at weeks 2 and 4 and then every 4
weeks for the duration of the study. At screening, the
trained observer assessed severity of glabellar rhytids using
the FWS: none = 0, mild = 1, moderate = 2, and severe =
3. Eligible subjects provided a medical history, including
previous and concomitant medication use, and underwent
an abbreviated physical examination.
The trained observer evaluated glabellar rhytids at each
follow-up visit using the FWS. Subjects evaluated their
glabellar rhytids at maximum attempted muscle contraction using the FWS. They also completed a self-evaluation
questionnaire that assessed feelings of attractiveness, selfconfidence, and satisfaction with appearance on a scale of 0
(not at all) to 6 (extremely) and rated the degree of improvement on a scale ranging from +4 (complete improvement,
100%) to ⫺4 (very marked worsening, at least 100%).
Protocol and Injection Technique
For the double-blind trial, participants were randomly
assigned into one of four possible treatment groups using a
block-of-eight design. On day 0 (baseline) of the trial, participants were treated with a total dose of either 20, 40, 60,
or 80 U botulinum toxin type A. The total dose was divided
among seven intramuscular injections into the muscles contributing to glabellar frown lines: 20% of the total dose
into the procerus muscle, 15% into each corrugator muscle,
and 50% over four sites in the orbicularis oculi (15% into
each of two sites above the medial canthus and 10% into
each of two sites above the midpupillary line; Figure 1).
This injection pattern was identical to the injection pattern
used in our similar study in females4 and was our standard
glabella injection pattern at the time of these studies.
Adverse Events
Signs and symptoms of adverse events were monitored
throughout the study. Investigators rated adverse events
for severity, seriousness, and relationship to treatment.
Severity was graded as mild, moderate, or severe. Serious
adverse events were those that were life threatening and
resulted in death, hospitalization, or persistent or signifi-
Masking
To maintain the blind, vials were prepared by a registered
nurse who took no further part in the study. Identicalappearing syringes were marked only with the participant
number. Injection volumes for a given site were constant
across doses to preserve masking. Total injected volume
was 0.4 mL for each participant (procerus 0.08 mL and
corrugator and medial orbicularis 0.06 mL each on both
sides, and midpupillary orbicularis 0.04 mL on each side).
The vials were reconstituted with nonpreserved saline to
final dilutions of 50 U/mL (20 U total dose), 100 U/mL (40
U total dose), 150 U/mL (60 U total dose), and 200 U/mL
(80 U total dose). A different vial was used for each participant, and injections were made within 1 hour of recon-
Figure 1. Botulinum toxin type A treatment injection sites: the procerus muscle, corrugator muscle, and orbicularis oculi. Injection sites
and percentage of total botulinum toxin type A injected at each site
are indicated.
Dermatol Surg
31:10:October 2005
1299
CARRUTHERS, J. AND A.: DOSE-RANGING STUDY OF MALE GLABELLAR RHYTIDS
cant disability or incapacity. The relationship to study
treatment was assessed as unrelated, possible, probable,
definite, or unknown.
Data Analysis and Statistical Methods
The selected sample size of 20 participants per treatment
group was based on an ␣ level of 0.05, a power of 0.8 to
0.9, and a potential dropout rate of 15%. All analyses of
efficacy and safety were conducted on the intent-to-treat
population, which included all participants assigned randomly to receive one of the four doses of botulinum toxin
type A and who underwent at least one efficacy assessment
while on treatment with the study drug.
Baseline Comparability
To evaluate baseline comparability, demographic data and
the pertinent medical history of participants were tabulated for each of the four treatment groups. A chi-square
test was used to analyze all categorical variables. Analysis
of variance was used for continuous variables.
Efficacy
The primary outcome measurements were the trained
observer’s assessment of the severity of wrinkles at maximum frown compared with baseline. Secondary efficacy
measures included the maximum treatment effect (greatest
change in category of FWS achieved as evaluated by the
trained observer), the response rate (percentage of partic-
ipants with a rating of none [0] or mild [1]), the percentage of participants with improvement from baseline, and
the subjects’ self-evaluations of response to treatment. The
primary efficacy data analysis was based on the duration
of effect or relapse rate, defined as a return to the baseline
value on the FWS at two consecutive visits and by comparison with baseline photographs, as evaluated by the
trained observer. The categorical data were analyzed using
a chi-square test; one-way analysis of variance was used to
evaluate changes in mean scores on the FWS. A survival
analysis of the time to relapse across treatment groups was
evaluated using the log rank and Wilcoxon tests.
Safety
Safety analyses were undertaken for the incidence and
severity of adverse events. The frequency of adverse events
by treatment group was assessed using a chi-square test.
Results
Demographics and Baseline Characteristics
Eighty participants were enrolled in the study. The four
treatment groups did not differ significantly in any baseline characteristics, including age, race, findings on physical examination, and FWS score at maximum attempted
contraction (Table 1). Of the 80 participants, 77 completed the study. Two participants withdrew consent, and
one discontinued without providing information.
Table 1. Patient Characteristics and Study Distribution
Treatment Group
Dose
Age (mean ⫾ SD)
Race
White
Hispanic
Asian
Other
20 U (n = 20)
44.2 ⫾ 14.6
40 U (n = 20)
38.6 ⫾ 8.2
60 U (n = 20)
44.0 ⫾ 12.8
80 U (n = 20)
39.6 ⫾ 13.2
20
0
0
0
18
0
0
2
19
0
1
0
16
1
0
3
2.95 (0.22)
2.90 (0.31)
2.95 (0.22)
3.0 (0.0)
Category at baseline, with contraction (n)
Moderate
Severe
1
19
2
18
1
19
0
20
Category at baseline, at rest (n)
None
Mild
Moderate
Severe
0
3
7
10
1
5
7
7
0
2
6
12
1
5
9
5
19 (95%)
1 (5%)
0 (0%)
19 (95%)
1 (5%)
0 (0%)
20 (100%)
0 (0%)
0 (0%)
19 (95%)
0 (0%)
1 (5%)
Baseline FWS (C); mean (SD)
Completed study
Withdrew consent
No information
C = maximum contraction; FWS = Facial Wrinkle Scale.
1300
CARRUTHERS, J. AND A.: DOSE-RANGING STUDY OF MALE GLABELLAR RHYTIDS
Efficacy: Trained Observer Assessments
Responder Rate
The maximum effects on glabellar lines obtained on the
FWS at full contraction are shown in Table 2. Across all
groups, 70 of the 80 participants (87.5%) experienced a
reduction in the severity of their glabellar lines from severe
to mild or none. In the 20 U group, 65% of participants
had an improvement in the FWS from severe to mild or
none; 90% and 95% of the participants in the 40 U and
60 U groups, respectively, and 100% of the participants in
the 80 U group had similar changes. Differences between
groups were statistically significant (p < .0001). In the 80
U group, 17 participants (85%) had a reduction in their
lines from severe to none. These differences in maximum
effect achieved by treatment group are reflected in the
changes in the mean FWS scores for each treatment group
over the course of the study (Figure 2). Patients in the 20
U dose consistently exhibited less of a decrease in mean
FWS scores throughout the study. Statistically significant
differences between groups were observed at weeks 2
through 12.
Responder rates are shown in Figure 3. For all treatment groups, the peak responder rate was observed
between weeks 2 and 4 and was 65% in the 20 U group
compared with 100% in the other dosage groups (p
< .0001). At 2 months, the responder rate was maintained
at 80% in the 80 U group and 90% in the 60 U group. It
Dermatol Surg
31:10:October 2005
fell to 50% in the 40 U group and 25% in the 20 U group.
The differences between groups were statistically significant (p = .0001). At the 3-month visit, 35% of the participants in both the 40 U and 60 U groups and 50% of participants in the 80 U group continued to be classified as
responders. In contrast, only 15% of participants in the 20
U group were classified as responders at 3 months.
Duration of Effect: Relapse Rate and Survival Analysis
A dose-response relationship was apparent in the duration
of the effect on the FWS at maximum attempted contraction. The mean time to relapse was 17.6 weeks for the 20
U dose, 21.7 for the 40 U dose, 22.8 for the 60 U dose, and
24.2 for the 80 U dose. The percentage of participants
relapsing at each visit is shown in Figure 4.
Based on the categorical analysis, one participant in the
20 U dose group relapsed by 2 months and five patients
relapsed by 3 months. In contrast, none of the participants
in the other three treatment groups had relapsed by 3
months (p = .0009). A significant difference among the
treatment groups was also detected at 4 months (p = .004),
which began to disappear by month 5 (p = .079). At month
5, 79% of participants receiving the 20 U dose had relapsed
compared with 63% at the 40 U dose, 50% at the 60 U
dose, and 40% at the 80 U dose. At 6 months, the relapse
rate was 90% for the 20 U dose, 74% for the 40 U dose,
75% for the 60 U dose, and 60% at the 80 U dose. Of all
participants, 26% (20 of 78) had not relapsed at 6 months.
Improvements from Baseline
Table 2. Maximum Effect Achieved on the Facial Wrinkle
Scale at Maximum Concentration (Trained Observer
Evaluations)
Number of Patients (%) by Dose
Effect Achieved
20 U
40 U
60 U
No change
Moderate–none
Severe–moderate
Severe–mild
Severe–none
1 (5)
1 (5)
5 (25)
12 (60)
1 (5)
0 (0)
2 (10)
0 (0)
12 (60)
6 (30)
0 (0)
1 (5)
0 (0)
9 (45)
10 (50)
80 U
0 (0)
0 (0)
0 (0)
3 (15)
17 (85)
The percentages of participants in each treatment group
showing any improvement from baseline, based on the
trained observer’s assessment at maximum contraction,
are shown in Figure 5. At 1 month, 85% of participants in
the 20 U group were improved over baseline compared
with 95% in the 40 U group and 100% in the 60 U and 80
U groups. By 2 months, 60% of the 20 U group, 90% of
the 40 U group, 100% of the 60 U group, and 95% of the
80 U group were rated as improved (p = .001). Statistically
significant differences were maintained at month 3, when
90% of the 80 U group continued to be rated as improved
(p = .0027).
Figure 2. Mean scores on the Facial Wrinkle Scale (FWS) at maximum contraction. *p < .0001; †p ⱕ .0234.
Dermatol Surg
31:10:October 2005
CARRUTHERS, J. AND A.: DOSE-RANGING STUDY OF MALE GLABELLAR RHYTIDS
1301
pants in the 20 U dose group were self-evaluated responders. At the 1-month visit, 75% of participants in the 80
U group continued to rate themselves as responders versus
20% in the 20 U group (p = .0027).
Improvements from Baseline
Figure 3. Responder rates (% of patients) by dose and visit; trained
observer assessment at maximum contraction.
Patients’ self-evaluations generally mirrored those of the
trained observer (Figure 6). By week 2, 45% of participants in the 20 U group reported improvement with contraction compared with 85% in the 40 U group and 90%
in each of the other two groups (p = .001). At 3 months,
75% of the participants in the 80 U group still reported an
improvement compared with 45% in the 60 U group, 65%
in the 40 U group, and 30% in the 20 U group (p = .023).
At month 4, 45% of the participants in the 80 U and 60 U
groups continued to report improvements. In the 40 U
group, 40% reported improvement from baseline, whereas
only 15% in the 20 U group reported improvements.
Global Improvement
Mean scores on the participants’ Global Assessment of
Improvement Scale (9-point scale) differed significantly
among groups at weeks 4 to 12. Generally, participants
who received the 20 U dose perceived the least degree of
improvement on the Global Assessment of Improvement
Scale. Those who were in the 80 U group had the highest
scores on the Global Assessment of Improvement Scale
(Figure 7).
Patient Questionnaire
Figure 4. Percentage of patients relapsing by dose and visit; trained
observer assessment at maximum contraction.
Patients reported increases in feelings of attractiveness,
self-confidence, and satisfaction with appearance on a
scale of 0 (not at all) to 6 (extremely). Significant differences between treatment groups in participants’ ratings of
attractiveness (p = .047) and feelings of satisfaction were
observed at week 2 (p = .0193). At month 1, treatment
group differences in ratings of attractiveness (p = .0052),
self-confidence (p = .0225), and feelings of satisfaction (p
= .0064) were detected.
Figure 5. Patients with an improvement from baseline; trained
observer assessment at maximum contraction.
Efficacy: Patient Self-Evaluations
Responder Rate
At the 2-week visit, 75% of participants in the 80 U dose
group rated themselves as responders on the FWS at maximum attempted contraction. In contrast, 35% of partici-
Figure 6. Patients with an improvement from baseline; patients’
self-assessment at maximum contraction.
1302
CARRUTHERS, J. AND A.: DOSE-RANGING STUDY OF MALE GLABELLAR RHYTIDS
Dermatol Surg
31:10:October 2005
Figure 7. Mean scores on the participants’ Global Assessment of Improvement Scale.
Safety
Botulinum toxin type A was generally well tolerated in all
participants, and there were no significant differences
between treatment groups in the number of participants
per group reporting an adverse event or in the number of
adverse events per group. Twelve adverse events were considered to be possibly or definitely treatment-related
(Table 3). All of these were transient and mild to moderate in severity. No association between botulinum toxin
type A dose and the occurrence of adverse events was
detected. Three severe adverse events were reported; none
were considered to be drug related.
Discussion
In male participants, botulinum toxin type A was highly
effective in reducing the appearance and severity of glabellar lines. On all measures, higher doses were more effective
and tended to provide more durable responses than the 20
U dose. Supporting a dose-response relationship on the
duration of the effect, the mean time to relapse was 21.7
Table 3. Treatment-Related Adverse Events
Treatment Group
20 U
40 U
60 U
80 U
(n = 20) (n = 20) (n = 20) (n = 20) Total
Adverse events
Bruise under
left eye
Headache
Brow/lid twitch
Heaviness in
brow/forehead
Forehead spasm/
muscle
contraction
(frontal area)
All events
1
0
0
0
1
0
0
0
3
2
0
0
1
0
0
0
2
3
3
2
0
0
0
2
2
1
5
2
4
12
weeks in the 40 U group, 22.8 weeks in the 60 U group,
and 24.2 weeks in the 80 U group. In contrast, the mean
time to relapse was 17.6 weeks for participants receiving
the 20 U dose. At 6 months post-treatment, the relapse
rate was 90% for the 20 U dose group compared with
74% for the 40 U dose group, 75% for the 60 U dose
group, and 60% for the 80 U dose group. Even so, 26%
of all participants had not relapsed at the 6-month visit.
The percentage of participants with improvements from
baseline according to both participant and trained
observer ratings was greater for the higher doses than for
the 20 U dose, and these differences persisted for up to 3
months. Similarly, the peak responder rate (the percentage
of participants with a rating of none or mild) was greater
in the higher-dose treatment groups according to both participant self-evaluations and trained observer ratings.
Overall, the benefits of treatment were most apparent at
maximum attempted contraction of the treated muscles.
There are minor inconsistencies in the results of this
study that we believe are due to the difficulties of performing esthetic studies with standardized treatment procedures. A much larger participant population would be
required to achieve greater consistency in the results; however, this is impractical, and the dose-response relationship
that we have demonstrated in many areas of the study is
sufficient. The major area in which the dose-response relationship is not observed is later in the study as participants
have relapsed; therefore, the number of individuals analyzed is smaller and more subject to variability. The inadequacy of the 20 U dose is clear, whereas the advantage of
higher doses is not as well demonstrated. We have therefore emphasized the superiority of the 40 U dose and
higher doses rather than the overall dose-response relationship.
The low rate of adverse events seen in the present study
further confirms the excellent safety profile of botulinum
toxin type A in esthetic use. The incidence of treatmentrelated adverse events was similar in all groups, and none
of these were severe or serious.
Dermatol Surg
31:10:October 2005
CARRUTHERS, J. AND A.: DOSE-RANGING STUDY OF MALE GLABELLAR RHYTIDS
This is the first systematic dose-ranging study undertaken in male participants. Although botulinum toxin type
A has been used in numerous trials, dosing was not consistent in earlier trials of botulinum toxin type A and has
not been standardized. Moreover, the majority of participants have been female.
A double-blind, randomized, dose-ranging study on the
treatment of glabellar lines in women demonstrated that a
10 U total dose was less efficacious than total doses of 20
U, 30 U, and 40 U.4 The peak response to treatment and
the duration of the benefit were dose dependent, but there
were no dose-related differences in adverse effects, thus
supporting the use of at least a 20 U total dose of botulinum toxin type A in females.
Taken together, the results from these two prospective,
double-blind, randomized, parallel-group trials support
previous clinical observations that the treatment of glabellar lines in men requires higher treatment doses of botulinum toxin type A than in women. In the current study,
the 40 U, 60 U, and 80 U doses were consistently more
effective than the 20 U dose in regard to both the extent
and the duration of effect, without any increase in the risk
of drug-related adverse events. Clinical benefits can typically be expected to last at least 3 to 4 months in most participants and up to 6 months in perhaps 25% of participants. Based on these findings, male participants with
glabellar rhytids appear to benefit from starting doses of at
least 40 U of botulinum toxin type A and probably higher.
At present, we start men at a dose approximately twice
that which we use in women (60–80 U).
The results of this study raise broader questions regarding the treatment of the male face. For example, should all
areas of the male face be treated at twice the dose used for
1303
females? This question needs further study because the
sensitivity of muscles to botulinum toxin type A can differ
markedly, and the results in one group of muscles, such as
the glabellar complex, should not be transposed to another
muscle or muscles. In addition, despite the very similar
responses of these male participants to the questions on
attractiveness, self-confidence, and satisfaction to the
responses of females, there are definite differences in the
male esthetic. Treatment of men should be adjusted
accordingly. This area requires further study and clinical
experience to ensure that we are giving our clients the optimal results from their botulinum toxin type A injections.
The results of this study refer to the Allergan formulation of botulinum toxin type A (BOTOX, BOTOX Cosmetic, Vistabel, Irvine, CA, USA) and cannot be generalized to any other formulations or serotypes of botulinum
toxin type A.
References
1. Botox Cosmetic (botulinum toxin type A) purified neurotoxin complex [package insert]. Irvine (CA): Allergan, Inc.; 2004.
2. Carruthers JA, Lowe NJ, Menter MA, et al. A multicenter, doubleblind, randomized, placebo-controlled study of the efficacy and
safety of botulinum toxin type A in the treatment of glabellar lines.
J Am Acad Dermatol 2002;46:840–9.
3. Carruthers JD, Lowe NJ, Menter MA, et al, for the Botox Glabellar
Lines II Study Group. Double-blind, placebo-controlled study of the
safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg 2003;112:1089–98.
4. Carruthers A, Carruthers J, Said S. Double-blind, randomized, parallel group, dose-ranging study of botulinum toxin type A
(BOTOX®, Allergan, Inc.) in the treatment of glabellar lines. Poster
presented at the European Academy of Dermatology and Venereology; 2001 Oct 10; Munich, Germany.